Other Vaccines - Morocco

Morocco

Highlights

The Other Vaccines market in Morocco is projected to reach a revenue of US$28.27m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 10.67%, resulting in a market volume of US$46.93m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$24.73bn in 2024.
Morocco's market for other vaccines is experiencing a surge in demand, driven by a growing awareness of preventive healthcare.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

Morocco, a country situated in North Africa, has been experiencing significant growth in its healthcare sector over the past few years. One of the areas that have been developing is the Other Vaccines market.

Customer preferences: Moroccan customers have become increasingly aware of the importance of vaccination in recent years. The government has been actively promoting vaccination campaigns, which has raised awareness among the population. Moreover, there has been a growing trend towards preventive healthcare, which has led to an increase in demand for vaccines.

Trends in the market: The Other Vaccines market in Morocco has been growing steadily over the past few years. The market has been driven by the increasing demand for vaccines, which has been supported by the government's efforts to promote vaccination. Moreover, the market has been expanding due to the growing number of private healthcare providers, which has increased access to vaccines.

Local special circumstances: Morocco has a relatively young population, with a median age of 29 years. This has contributed to the growing demand for vaccines, as young people are more likely to be aware of the importance of preventive healthcare. Additionally, the country has a high infant mortality rate, which has led to a focus on childhood vaccination programs.

Underlying macroeconomic factors: Morocco has been experiencing steady economic growth over the past few years, which has contributed to the growth of the healthcare sector. The government has been investing in healthcare infrastructure, which has increased access to healthcare services, including vaccines. Moreover, the country has been attracting foreign investment in the healthcare sector, which has led to the introduction of new vaccines and technologies.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.